We advised the underwriters on the SEC-registered equity offering

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $173.4 million SEC-registered offering by IVERIC bio Inc. of 10,350,000 shares of common stock, including the full exercise by the underwriters of their option to purchase 1,350,000 additional shares of common stock. IVERIC’s common stock is listed on the Nasdaq Global Select Market under the symbol “ISEE.”

Based in New York, New Jersey and Massachusetts, IVERIC is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. IVERIC is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retina diseases including all stages of age-related macular degeneration.

The Davis Polk corporate team included partners Roshni Banker Cariello and Richard D. Truesdell Jr. and associates Jeannette Safi, Taeo I. Carse and Michael Schuster. The tax team included partner Ethan R. Goldman and associate Dov Sussman. Partner Pritesh P. Shah and associate Hilary Smith provided intellectual property advice. All members of the Davis Polk team are based in the New York office.